Transaction streamlines operations and positions Gaxos to focus on revenue-generating, higher-margin opportunities Roseland, NJ, June 24, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ( GXAI ) (Gaxos or the Company), a company developing artificial intelligence applications across various high-growth sectors, today announced that it had completed the sale of its gaming assets, including its portfolio of mobile games and Gaxos Gaming...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

June 24 (Reuters) - Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth up to about $1.9 billion, aiming to develop therapies for historically hard-to-drug cancer targets. Here are some details of the deal: * Antares Therapeutics said it will receive $105 million upfront under the agreement with Novartis. * The biotech is also...